Parabilis Medicines, Inc.
24.44USD
-2.4800 (-9.21%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on PBLS.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|
| Revenue | 0 | — | 0 | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Income | -51 | — | -37 | — |
| Net Income | -52 | -45 | -35 | -38 |
| EPS (Diluted) | -$2.32 | — | -$22.28 | — |
Source: SEC filings (EDGAR)